Editing human hematopoietic stem cells: advances and challenges

被引：8
作者：
Bhoopalan, Senthil Velan [1 ,2 ]
Yen, Jonathan S. [1 ]
Levine, Rachel M. [1 ]
Sharma, Akshay [2 ,3 ]
机构：
[1] St Jude Childrens Res Hosp, Dept Hematol, Memphis, TN USA
[2] St Jude Childrens Res Hosp, Dept Bone Marrow Transplantat & Cellular Therapy, Memphis, TN USA
[3] St Jude Childrens Res Hosp, Dept Bone Marrow Transplantat & Cellular Therapy, 262 Danny Thomas Pl, MS1130, Memphis, TN 38105 USA
来源：
CYTOTHERAPY | 2023年 / 25卷 / 03期
关键词：
CRISPR-Cas9; hematopoietic stem cells; severe congenital neutropenia; sickle cell disease; GENE-THERAPY; ALPHA-GLOBIN; BASE EDITORS; GENOMIC DNA; TARGET; RNA; CAS9; SPECIFICITIES; COLLECTION; NUCLEASES;
D O I：
10.1016/j.jcyt.2022.08.003
中图分类号：
Q813 [细胞工程];
学科分类号：
摘要：
Genome editing of hematopoietic stem and progenitor cells is being developed for the treatment of several inherited disorders of the hematopoietic system. The adaptation of CRISPR-Cas9-based technologies to make precise CHANGES TO THE GENOME, and developments in altering the specificity and efficiency, and improving the delivery of nucleases to target cells have led to several breakthroughs. Many clinical trials are ongoing, and several pre-clinical models have been reported that would allow these genetic therapies to one day offer a potential cure to patients with diseases where limited options currently exist. However, there remain several challenges with respect to establishing safety, expanding accessibility and improving the manufacturing pro -cesses of these therapeutic products. This review focuses on some of the recent advances in the field of genome editing of hematopoietic stem and progenitor cells and illustrates the ongoing challenges.(c) 2022 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码：261 / 269
页数：9
相关论文
共 135 条
  • [21] Therapeutic gene editing in CD34+ hematopoietic progenitors from Fanconi anemia patients
    Diez, Begona
    Genovese, Pietro
    Roman-Rodriguez, Francisco J.
    Alvarez, Lara
    Schiroli, Giulia
    Ugalde, Laura
    Rodriguez-Perales, Sandra
    Sevilla, Julian
    Diaz de Heredia, Cristina
    Holmes, Michael C.
    Lombardo, Angelo
    Naldini, Luigi
    Antonio Bueren, Juan
    Rio, Paula
    [J]. EMBO MOLECULAR MEDICINE, 2017, 9 (11) : 1574 - 1588
  • [22] Epidemiology of Congenital Neutropenia
    Donadieu, Jean
    Beaupain, Blandine
    Mahlaoui, Nizar
    Bellanne-Chantelot, Christine
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2013, 27 (01) : 1 - +
  • [23] Hemoglobin S polymerization and sickle cell disease: A retrospective on the occasion of the 70th anniversary of Pauling's Science paper
    Eaton, William A.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (02) : 205 - 211
  • [24] Cas9 activates the p53 pathway and selects for p53-inactivating mutations
    Enache, Oana M.
    Rendo, Veronica
    Abdusamad, Mai
    Lam, Daniel
    Davison, Desiree
    Pale, Sangita
    Currimjee, Naomi
    Hess, Julian
    Pantel, Sasha
    Nag, Anwesha
    Thorner, Aaron R.
    Doench, John G.
    Vazquez, Francisca
    Beroukhim, Rameen
    Golub, Todd R.
    Ben-David, Uri
    [J]. NATURE GENETICS, 2020, 52 (07) : 662 - +
  • [25] Clinically relevant gene editing in hematopoietic stem cells for the treatment of pyruvate kinase deficiency
    Fananas-Baquero, Sara
    Quintana-Bustamante, Oscar
    Dever, Daniel P.
    Alberquilla, Omaira
    Sanchez-Dominguez, Rebeca
    Camarena, Joab
    Ojeda-Perez, Isabel
    Dessy-Rodriguez, Mercedes
    Turk, Rolf
    Schubert, Mollie S.
    Lattanzi, Annalisa
    Xu, Liwen
    Lopez-Lorenzo, Jose L.
    Bianchi, Paola
    Bueren, Juan A.
    Behlke, Mark A.
    Porteus, Matthew
    Segovia, Jose-Carlos
    [J]. MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2021, 22 : 237 - 248
  • [26] Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?
    Fitzhugh, Courtney D.
    Hsieh, Matthew M.
    Bolan, Charles D.
    Saenz, Carla
    Tisdale, John F.
    [J]. CYTOTHERAPY, 2009, 11 (04) : 464 - 471
  • [27] FUNCTIONAL-HETEROGENEITY IS ASSOCIATED WITH THE CELL-CYCLE STATUS OF MURINE HEMATOPOIETIC STEM-CELLS
    FLEMING, WH
    ALPERN, EJ
    UCHIDA, N
    IKUTA, K
    SPANGRUDE, GJ
    WEISSMAN, IL
    [J]. JOURNAL OF CELL BIOLOGY, 1993, 122 (04) : 897 - 902
  • [28] CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
    Frangoul, H.
    Altshuler, D.
    Cappellini, M. D.
    Chen, Y-S
    Domm, J.
    Eustace, B. K.
    Foell, J.
    de la Fuente, J.
    Grupp, S.
    Handgretinger, R.
    Ho, T. W.
    Kattamis, A.
    Kernytsky, A.
    Lekstrom-Himes, J.
    Li, A. M.
    Locatelli, F.
    Mapara, M. Y.
    de Montalembert, M.
    Rondelli, D.
    Sharma, A.
    Sheth, S.
    Soni, S.
    Steinberg, M. H.
    Wall, D.
    Yen, A.
    Corbacioglu, S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (03) : 252 - 260
  • [29] Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases
    Frock, Richard L.
    Hu, Jiazhi
    Meyers, Robin M.
    Ho, Yu-Jui
    Kii, Erina
    Alt, Frederick W.
    [J]. NATURE BIOTECHNOLOGY, 2015, 33 (02) : 179 - 186
  • [30] Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice
    Gao, Chunyan
    Schroeder, Jocelyn A.
    Xue, Feng
    Jing, Weiqing
    Cai, Yuanhua
    Scheck, Amelia
    Subramaniam, Saravanan
    Rao, Sridhar
    Weiler, Hartmut
    Czechowicz, Agnieszka
    Shi, Qizhen
    [J]. BLOOD ADVANCES, 2019, 3 (18) : 2700 - 2711
12345678910